Status: Recruiting
A Study of MI226 Injection for Abdominal Fat Accumulation
This is a Phase 1, randomized, double-blind (with open-label sentinel cohorts), placebo-controlled, single-ascending-dose study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of MI226 Injection in participants with abdominal fat accumulation.
Participants needed: 52
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Nanjing Minova Pharmaceutical Co., Ltd.Updated: Aug 6, 2026Locations: 1
Eligibility criteria
Aged ≥18 and <65 years at the time of screening. [+4]
Presence of any medical or physical condition that, in the judgment of the inves... [+8]